MorphoSys AG announced upcoming presentations of data on the company's proprietary hemato-oncological programmes MOR208 and MOR202 at the 58th American Society of Hematology (ASH) Annual Meeting, being held December 3-6, 2016 in San Diego, California/USA.
"We are pleased that updated clinical trial results with our antibodies MOR208 and MOR202 in patients with B-cell malignancies and multiple myeloma, respectively, will be shown at the upcoming ASH conference as oral presentations," commented Dr. Arndt Schottelius, chief development officer of MorphoSys AG. "We expect this will further demonstrate the potential of our proprietary development candidates for patients suffering from those hemato-oncological malignancies that have a particularly high unmet medical need."
The oral presentation will include updated clinical results, in particular with respect to duration of responses, from a phase 2a MOR208 monotherapy trial in adult patients with relapsed/refractory NHL including DLBCL and iNHL.
It will also include updated safety and efficacy results from the ongoing phase 1/2a MOR202 dose-escalation study in pre-treated multiple myeloma patients. Results will in particular include maturing data from the MOR202 8mg/kg patient cohorts in combination with lenalidomide and pomalidomide as well as first results from the highest dose cohorts of 16mg/kg MOR202 in combination with lenalidomide and pomalidomide.
The poster presentation will include safety and efficacy results from the ongoing phase 2 investigator initiated trial (IIT) of MOR208 in combination with lenalidomide or ibrutinib in CLL.